drugset / Trial / NCT06166615

The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence

NCT06166615

Phase 2/3 Unknown 148 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This clinical trial aims to assess the effectiveness of Ramosetron compared to Psyllium, a gold standard therapy, in patients with fecal incontinence. The primary questions it seeks to answer are: 1. Does Ramosetron improve the symptoms of fecal incontinence? 2. Is Ramosetron superior to Psyllium in terms of symptom improvement and its impact on quality of life? Participants will be randomly assigned to one of two groups, either taking Ramosetron or Psyllium for one month. They will be asked to complete a questionnaire. Researchers will then compare the Fecal Incontinence Severity Index between the Ramosetron and Psyllium groups to determine whether Ramosetron provides superior symptom relief compared to Psyllium.

Timeline

Start
2023-12-15
Primary completion
2024-05-30
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator PLANTAGO SEED Other / unclassified 12 g Oral
Subject Ramosetron Small molecule 2.5 ug Oral
Subject Ramosetron Small molecule 5 ug Oral

Indications

No indication recorded.